News Conference News TCT 2024 Pooled All-Female Analysis Support Benefits of TAVI Over SAVR L.A. McKeown November 01, 2024
News Conference News TCT 2024 EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis Michael O'Riordan October 28, 2024
News Conference News TCT 2024 EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS L.A. McKeown October 28, 2024
Presentation TCT 2023 I Have a Crystal Ball: What Will the AVR Universe Look Like in 2030? Presenter: Bernard Prendergast October 25, 2023
News Conference News TCT 2022 Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year L.A. McKeown September 23, 2022
Presentation TCT 2022 Management of Concomitant Coronary Disease in AVR-Eligible Patients – COMPLEAT or NOT? Presenter: David Wood September 17, 2022
News Conference News TCT 2021 TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3 Yael L. Maxwell November 05, 2021
News Conference News TCT 2020 Valve Disease Plus COVID-19 Often a Lethal Combination, Registry Shows Caitlin E. Cox October 14, 2020
News Conference News TCT 2018 Prosthetic Valve Endocarditis Rate Similarly Low for TAVR vs SAVR TCT Daily Staff September 28, 2018
News Conference News TCT 2017 TAVR Beats Out SAVR, at Least In-Hospital, for Patients With Prior CABG Ashley Lyles November 08, 2017
News Conference News TCT 2016 Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients Todd Neale November 02, 2016
Presentation TCT 2016 Current Indications for TAVR: When Is TAVI Better Than Surgical AVR? Presenter: Ziyad M. Hijazi, David W.M. Muller November 01, 2016
Presentation TCT 2016 Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Con Position Presenter: Niall T. Mulvihill, Hellmuth Weich October 31, 2016
Presentation TCT 2016 Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Pro Position Presenter: Niall T. Mulvihill, Antoniette Neylon October 31, 2016
Presentation TCT 2016 Debate: TAVR for Low Risk Patients Is It time? NO, We Dont Yet Know if Its as Durable as Surgical AVR! Presenter: Russell A. Brandwein, Isaac George October 30, 2016